menu
    • menu
    [{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"Steroid 5-alpha reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Dutasteride

    Menu

    Dutasteride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Dongkook Pharmaceutical

    South Korea arrow
    Conjugates Summit
    Not Confirmed

    Dongkook Pharmaceutical

    South Korea arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dutasteride,Tadalafil

    Therapeutic Area : Urology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Will Dongkook Pharm Present New Combo Therapy for BPH?

    Details : DKF-313 is a combination of dutasteride (5α-reductase inhibitor) and tadalafil (PDE5 inhibitor). It is being evaluated in phase 3 clinical trials for the treatment of benign prostatic hyperplasia.

    Product Name : DKF-313

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 26, 2023

    Lead Product(s) : Dutasteride,Tadalafil

    Therapeutic Area : Urology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Yuyu Pharma

    South Korea arrow
    Conjugates Summit
    Not Confirmed

    Yuyu Pharma

    South Korea arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dutasteride

    Therapeutic Area : Dermatology

    Study Phase : Preclinical

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment

    Details : Dutasteride inhibits both Type I and Type II 5-alpha reductase which act to transform testosterone, a male hormone, into a DHT hormone. In scientific studies, excess DHT is understood to be the cause of hair loss.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 29, 2022

    Lead Product(s) : Dutasteride

    Therapeutic Area : Dermatology

    Highest Development Status : Preclinical

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Corpometria Institute

    Country arrow
    European Coatings Show
    Not Confirmed

    Corpometria Institute

    Country arrow
    European Coatings Show
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dutasteride,Ivermectin,Azithromycin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Undisclosed

    Sponsor : Applied Biology

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Applied Biology in Collaboration with Corpometria Institute to Launch ANDROCOV TRIAL for COVID-19

    Details : ANDROCOV trial is for a Generic Anti-androgen as a Treatment For COVID-19 taking Dutasteride, Ivermectin, Azithromycin and Proxalutamide under combination.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    September 11, 2020

    Lead Product(s) : Dutasteride,Ivermectin,Azithromycin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Undisclosed

    Sponsor : Applied Biology

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth